Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria

Detalhes bibliográficos
Autor(a) principal: Campos, Débora Leite [UNESP]
Data de Publicação: 2022
Outros Autores: Demarqui, Fernanda Manaia [UNESP], Solcia, Mariana Cristina [UNESP], de Souza, Paula Carolina [UNESP], da Silva Maia, Pedro Ivo, Deflon, Victor Marcelo, Pavan, Fernando Rogério [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.3390/biomedicines10102398
http://hdl.handle.net/11449/249301
Resumo: As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.
id UNSP_87185ef874b85f00cf58a3a0d092ecb2
oai_identifier_str oai:repositorio.unesp.br:11449/249301
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacterialatent tuberculosisMycobacterium tuberculosistreatmentAs a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Tuberculosis Research Laboratory School of Pharmaceutical Sciences São Paulo State University—UNESPInstitute of Exact Natural Sciences and Education Triangulo Mineiro Federal University—UFTMTuberculosis Research Laboratory School of Pharmaceutical Sciences São Paulo State University—UNESPCNPq: 303603/2018-6Universidade Estadual Paulista (UNESP)Triangulo Mineiro Federal University—UFTMCampos, Débora Leite [UNESP]Demarqui, Fernanda Manaia [UNESP]Solcia, Mariana Cristina [UNESP]de Souza, Paula Carolina [UNESP]da Silva Maia, Pedro IvoDeflon, Victor MarceloPavan, Fernando Rogério [UNESP]2023-07-29T15:12:21Z2023-07-29T15:12:21Z2022-10-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/biomedicines10102398Biomedicines, v. 10, n. 10, 2022.2227-9059http://hdl.handle.net/11449/24930110.3390/biomedicines101023982-s2.0-85140604528Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengBiomedicinesinfo:eu-repo/semantics/openAccess2024-06-24T13:08:15Zoai:repositorio.unesp.br:11449/249301Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462024-06-24T13:08:15Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
title Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
spellingShingle Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
Campos, Débora Leite [UNESP]
latent tuberculosis
Mycobacterium tuberculosis
treatment
title_short Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
title_full Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
title_fullStr Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
title_full_unstemmed Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
title_sort Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
author Campos, Débora Leite [UNESP]
author_facet Campos, Débora Leite [UNESP]
Demarqui, Fernanda Manaia [UNESP]
Solcia, Mariana Cristina [UNESP]
de Souza, Paula Carolina [UNESP]
da Silva Maia, Pedro Ivo
Deflon, Victor Marcelo
Pavan, Fernando Rogério [UNESP]
author_role author
author2 Demarqui, Fernanda Manaia [UNESP]
Solcia, Mariana Cristina [UNESP]
de Souza, Paula Carolina [UNESP]
da Silva Maia, Pedro Ivo
Deflon, Victor Marcelo
Pavan, Fernando Rogério [UNESP]
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (UNESP)
Triangulo Mineiro Federal University—UFTM
dc.contributor.author.fl_str_mv Campos, Débora Leite [UNESP]
Demarqui, Fernanda Manaia [UNESP]
Solcia, Mariana Cristina [UNESP]
de Souza, Paula Carolina [UNESP]
da Silva Maia, Pedro Ivo
Deflon, Victor Marcelo
Pavan, Fernando Rogério [UNESP]
dc.subject.por.fl_str_mv latent tuberculosis
Mycobacterium tuberculosis
treatment
topic latent tuberculosis
Mycobacterium tuberculosis
treatment
description As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.
publishDate 2022
dc.date.none.fl_str_mv 2022-10-01
2023-07-29T15:12:21Z
2023-07-29T15:12:21Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3390/biomedicines10102398
Biomedicines, v. 10, n. 10, 2022.
2227-9059
http://hdl.handle.net/11449/249301
10.3390/biomedicines10102398
2-s2.0-85140604528
url http://dx.doi.org/10.3390/biomedicines10102398
http://hdl.handle.net/11449/249301
identifier_str_mv Biomedicines, v. 10, n. 10, 2022.
2227-9059
10.3390/biomedicines10102398
2-s2.0-85140604528
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Biomedicines
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv repositoriounesp@unesp.br
_version_ 1826304465439817728